EP4142945A2 - Method and portable device for detection of nucleic sequences in suspected coronavirus samples - Google Patents
Method and portable device for detection of nucleic sequences in suspected coronavirus samplesInfo
- Publication number
- EP4142945A2 EP4142945A2 EP21723396.4A EP21723396A EP4142945A2 EP 4142945 A2 EP4142945 A2 EP 4142945A2 EP 21723396 A EP21723396 A EP 21723396A EP 4142945 A2 EP4142945 A2 EP 4142945A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- portable device
- samples
- amplification
- dna
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- 241000711573 Coronaviridae Species 0.000 title claims description 26
- 230000003321 amplification Effects 0.000 claims abstract description 75
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 75
- 238000006243 chemical reaction Methods 0.000 claims abstract description 52
- 238000011901 isothermal amplification Methods 0.000 claims abstract description 46
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 41
- 238000010839 reverse transcription Methods 0.000 claims abstract description 37
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 31
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 31
- 238000004458 analytical method Methods 0.000 claims abstract description 23
- 239000003155 DNA primer Substances 0.000 claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 20
- 230000007613 environmental effect Effects 0.000 claims abstract description 12
- 108020004414 DNA Proteins 0.000 claims description 60
- 102000053602 DNA Human genes 0.000 claims description 48
- 239000000523 sample Substances 0.000 claims description 44
- 229920002477 rna polymer Polymers 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 21
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 18
- 239000002751 oligonucleotide probe Substances 0.000 claims description 18
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 102100034343 Integrase Human genes 0.000 claims description 16
- 238000006073 displacement reaction Methods 0.000 claims description 15
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 239000013615 primer Substances 0.000 claims description 13
- 239000011541 reaction mixture Substances 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 210000003608 fece Anatomy 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 238000009830 intercalation Methods 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 210000001989 nasopharynx Anatomy 0.000 claims description 5
- -1 oral swabs Chemical class 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 claims description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 2
- 239000004065 semiconductor Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 238000005286 illumination Methods 0.000 claims 3
- 239000007793 ph indicator Substances 0.000 claims 1
- 229920002120 photoresistant polymer Polymers 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 description 43
- 238000007397 LAMP assay Methods 0.000 description 27
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 208000025721 COVID-19 Diseases 0.000 description 10
- 230000004544 DNA amplification Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108020000999 Viral RNA Proteins 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000002211 ultraviolet spectrum Methods 0.000 description 4
- 238000001429 visible spectrum Methods 0.000 description 4
- 241000450599 DNA viruses Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000494545 Cordyline virus 2 Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102100026816 DNA-dependent metalloprotease SPRTN Human genes 0.000 description 2
- 101710175461 DNA-dependent metalloprotease SPRTN Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000701844 Bacillus virus phi29 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 101100491338 Mus musculus Anapc1 gene Proteins 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/023—Sending and receiving of information, e.g. using bluetooth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0663—Whole sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1822—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using Peltier elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1827—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using resistive heater
Definitions
- the present invention refers to a method and a portable device for the detection and identification of specific nucleic acids sequences in different types of samples, by means of an optimised reverse transcriptase technique and/or isothermal amplification, usinq specific oliqonucleotide primers of the tarqet reqion(s) to detect, whereby the amplification of the same is conducted in an indirect and non-specific manner, or direct and specific, usinq discriminatory amplification reaqents, which siqnal, colourimetric or fluorescent, is recorded by a portable device where the reaction is carried out, havinq useful application for different types of diaqnostics in different clinical, pharmaceutical, veterinary, food, environmental, biotechnoloqical, or biosafety areas.
- PCR polymerase chain reaction
- the diagnostics by means of the normal or real time PCR suffers from limitations which prohibits it from being applied to Point-of-Care diagnostics (PoC). Namely, they require specialised and costly staff and equipment, take several hours to provide a result and are easily susceptible to being inhibited by contaminants that are frequently present in the samples to be analysed (such as, for example, haemoglobin, salts, chelators, alcohols, among others) this being the main reason for the failure in amplification even in the presence of sufficient copies of target nucleic acid to amplify, leading to false negatives.
- the real-time PCR technology adds the limitation that a multiplex reaction is limited to the detection capacity of the apparatus, and further, that a high technical and knowledge capacity are needed to develop a new test, which is not available in a commercial kit.
- LAMP Loop-mediated isothermal amplification
- LAMP is a DNA amplification technique.
- the RT-LAMP combines LAMP with a reverse transcription step to allow RNA detection. This technique is isothermal, being executed at a constant temperature and does not require a thermal cycler.
- the target sequence is amplified at a constant temperature of 60-65 °C using several sets of oligonucleotide primers and a polymerase with high strand-displacement, as well as the replication capacity.
- the amplified product can be detected by photometry, measuring the turbidity caused by the precipitate in solution, which is produced as a secondary product of the amplification, or by colour change of pH sensitive dye, which varies as a consequence of the polymerase activity during the amplification. This allows detection of the amplification to the naked eye with a simple apparatus.
- the reaction can be detected in real time measuring the turbidity or by fluorescence, using for such intercalating fluorophores such as SYTOTM 9.
- fluorophores such as SYBRTM green can be used to create a visible colour change without the need for expensive detection equipment.
- SYBRTM green can be used to create a visible colour change without the need for expensive detection equipment.
- the fluorophore molecules intercalate with the DNA, there is a correlation with the amplification of the same, therefore the LAMP can be quantitative.
- LAMP is a relatively new DNA amplification technique that due to its simplicity and low cost can bring several benefits. LAMP can be used in field studies and PoC tests. The LAMP technique has shown more robust results regarding the inhibitors of the normal PCR reactions in blood samples, which allows the application of the technique in cases where the optimum extraction of DNA and RNA is not possible.
- LAMP is less versatile than PCR since, although it is primarily useful as a detection tool, it does not allow all the other molecular biology techniques of PCR. Since LAMP uses 4 to 6 target regions for the oligonucleotide primers it is also extremely difficult to design oligonucleotide primers for the technique.
- One of the consequences of such a cocktail of oligonucleotide primers is the increase in non-specific amplifications, and consequent false positives, which by using a DNA strand- displacement polymerase without exonuclease activity does not allow the use of Taqman probes, for example, nor do the indirect methods allow said false positives to be discriminated.
- HDA uses a helicase enzyme to generate single-stranded templates for hybridisation of oligonucleotide primers and subsequent extension of the oligonucleotide primer by a polymerase.
- the HDA offers several advantages over other isothermal DNA amplification methods, having a simple reaction scheme and being an isothermal reaction, which can be carried out at a single and constant temperature during the entire process. These properties offer a great potential for the development of simple portable devices for DNA diagnostic to be used in loco and in PoC.
- HDA high-density polymerase chain reaction
- PCR reactions carried out in a thermal cycler that can contain plates of samples from several wells allow the amplification and detection of the intended target DNA a from a maximum of 96 samples at a time.
- the cost of purchasing reagents for HDA is also relatively expensive in comparison with the reagents for the PCR reagents (Vincent M et al (2004) EMBO, 5(8):795-800.
- RCA Rolling Circle Amplification
- RCA was developed as a simplified version of the Rolling Circle Replication, an isothermal DNA amplification technique.
- the RCA mechanism is widely used in molecular biology and biomedical nanotechnology, particularly in the field of biosensing (as a method for signal amplification).
- RCA was used successfully to detect the existence of viral and bacterial DNA from clinical samples, which is extremely beneficial for the rapid diagnostic of infectious diseases. It was also used as a method for on-chip signal amplification, for nucleic acid microarrays (both for DNA as for RNA).
- the RCA technique can also be applied to the construction of DNA nanostructures and DNA hydrogels.
- the RCA products can also be used as templates for periodic assembly of nano species or proteins, synthesis of metallic nanowires and formation of nano-islands.
- RCA is a highly versatile DNA amplification tool, widely used in many fields where the limitations of sensitivity and/or specificity, preparation of laborious samples and/or signal amplification procedures had previously prevented the use of other tools.
- SDA Strand Displacement Amplification
- MDA Multiple Displacement Amplification
- SDA and MDA are DNA amplification techniques without resorting to PCR. These methods can rapidly amplify minimum DNA sample quantifies sufficient for a genomic analysis.
- the reaction starts by annealing random hexamer oligonucleotide primers to the template: the DNA synthesis is carried out by a high-fidelity enzyme at a constant temperature.
- SDA is an isothermal in vitro technique for amplification of nucleic acids, based on the Hind-I capacity of cutting the non- modified strand of a form of hemi-phosphorothioate from the recognised location thereof and the capacity of the exonuclease-deficient klenow (exo-klenow) to extend the 3' end and dislocate the DNA strand downstream.
- the exponential amplification results from the coupling of the sense and anti-sense reactions wherein the displaced strands of a sense reaction serve as target for an anti-sense reaction and vice- versa.
- ADO Allelic dropout
- RPA Recombinase Polymerase Amplification
- RPA is an isothermal alternative to the PCR reaction.
- a reverse transcriptase enzyme By adding a reverse transcriptase enzyme to an RPA reaction, we can detect both RNA and DNA, without the need for a separate step to produce cDNA.
- RPA uses much simpler equipment than the PCR.
- TMA Transcription Mediated Amplification
- NASBA Nucleic Acid Sequenced Based Amplification
- Both TMA and NASBA are isothermal amplification reactions that imitate the replication of the retroviral RNA. Both are specific for target RNA sequences and have achieved popularity since they demonstrated a wide range of applications to detect pathogen agents in clinical, environmental, and food samples. Both have commercially available kits.
- the NASBA and the TMA have the advantage of not requiring a thermal cycler protocol. Both techniques use RNA polymerase to produce RNA from a promoter created in the region of oligonucleotide primers and a reverse transcriptase, to produce DNA from RNA templates. For the TMA, the reverse transcriptase itself degrades the initial RNA template as it synthesizes the complementary DNA thereof.
- RNA amplification technique was improved, with the introduction of a third enzymatic activity, the RNase H, to destroy the RNA from the CDNA without the step of heat denaturation.
- the oligonucleotide forward primer binds with any target RNA present in a sample.
- the reverse transcriptase enzymes and RNase H together with the reverse oligonucleotide primer, produce a dsDNA with the target sequence and a T7 promoter.
- the polymerase of RNA dependent on DNA T7 uses this dsDNA to produce many RNA complementary strands to the original target RNA.
- each recently synthesised RNA can be copied in a cyclic phase, resulting in an exponential amplification of the RNA that is complementary to the target.
- the thermal cycling step was eliminated, generating an isothermal amplification method named self-sustained sequence replication.
- the final products of NASBA and TMA can be detected using gel electrophoresis and colourimetric test.
- the new coronavirus named "SARS-CoV-2" was detected for the first time in China in December 2019 and, since 11 March 2020, has been classified as a pandemic by the WHO, causing a respiratory disease called "COVID-19".
- the coronaviruses are a large family of common viruses in people and in many different species of animals, including camels, cattle, cats, and bats.
- the animal coronaviruses rarely can infect human beings and subsequently transmit themselves among people such as the MERS-CoV, SARS-CoV and now this new virus SARS-CoV-2. While we are still learning how it disseminates and the severity of the disease that it causes, this new COVID-19 disease has rapidly spread to more than 100 locations throughout the world.
- the diagnostic of the COVID-19 disease, caused by the SARS-CoV-2 virus is performed mainly by the molecular pathway, and the chosen diagnostic means for this type of diagnostic is a real-time PCR, there being a series of commercial kits available (for example, cobas SARS-CoV-2 (Roche), TaqPath COVID-19 Combo Kit (Thermo Fisher), lcopy COVID-19 QPCR Kit (1DROP Inc), Abbott Real-time SARS-COV-2 (Abbott)).
- the portable device that was developed allows the rapid detection ( ⁇ 30 minutes) of the presence of the virus (SARS-Cov-2) in several types of samples, whereby it may be used by any person (layperson in this field) and as it is portable, allowing this test to be carried out virtually anywhere. All of this eliminates the risk of contagion between the potentially infected person and the health professionals who before were involved in the process of collection and analysis of the samples. Notwithstanding, the tracking of positive results by the health entities is also able to be performed in real time, since the diagnostic is made by means of a mobile device which communicates with the portable device and sends all the information to a remote server in the cloud.
- the portable device comprises a battery, and the truly small dimension thereof (in other words, it fits in a coat pocket), makes it truly portable for PoC.
- the present invention refers to an integrated system and method for the detection and identification of specific sequences of nucleic acids in different types of samples with the presence of a portable device (1) controlled by a mobile application (9) which records the data acquired by the portable device (1), analyses and stores it in a remote server in a cloud (10) and method for the detection and identification of specific nucleic acid sequences in different types of samples.
- the mobile application (9) also records the data acquired by the portable device (1), analyses and stores it in a remote server in a cloud (10) wherein the latter, in turn, analyses the global set of all the data in order to allow the global analysis of, for example, the evolution of epidemics.
- FIG. 1 Scheme of the components of the portable device (1) controlled by a mobile application (9) and connected directly or indirectly to a remote server in a cloud (10).
- Figure 2 Example of a test with a negative sample carried out and monitored on the portable device (1), for the Gene N, using a specific oligonucleotide probe marked with fluorophore FAM. The intensity of the fluorescence is maintained unaltered throughout the entire test, demonstrating that the reverse transcription and isothermal amplification did not occur, due to the absence of the target viral RNA.
- Figure 3 Example of a test with a positive sample carried out and monitored on the portable device (1), for the Gene N, using a specific oligonucleotide probe marked with fluorophore FAM. An exponential increase in the intensity of the fluorescence is verified from ⁇ 1100seconds, a consequence of the reverse transcription and isothermal amplification, disputed by the presence of the target viral
- the present invention refers to an integrated system for the detection and identification of specific sequences of nucleic acids in suspected coronavirus samples with the presence of a portable device (1) controlled by a mobile application (9) which records the data acquired by the portable device (1), analyses and stores it in a remote server in a cloud (10).
- the detection and identification of the specific sequences of nucleic acids in suspected coronavirus samples is carried out by means of an optimised reverse transcriptase and/or isothermal amplification technique, usinq specific oliqonucleotide primers of the tarqet reqion(s) to detect, whereby the amplification of the same is carried out in an indirect and non-specific manner, or direct and specific, usinq discriminatory amplification reaqents, which siqnal, colourimetric or by fluorescence, is recorded by a portable device (1) where the reaction is executed, beinq controlled by a mobile application (9) and connected directly or indirectly to a remote server in a cloud (10), and havinq useful application for different types of diaqnostic in different clinical, pharmaceutical, veterinary, food, environmental, biotechnoloqical , and biosafety areas.
- an optimised reverse transcriptase and/or isothermal amplification technique usinq specific oliqonucleotide primer
- the present invention further refers to a method for the detection and identification of the referred specific nucleic acid sequences in suspected coronavirus samples.
- the present invention is useful for the detection and identification of relevant nucleic sequences for different types of diagnostic in different pharmaceutical, veterinary, food, environmental, biotechnological, or biosafety areas, being particularly useful in the rapid diagnostic, with low cost and a point of interest for the SARS-CoV-2 virus.
- the nucleic acid sequences to be detected with the said method are sequences of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
- sequences of nucleic acids are of human, animal and/or pathogen origin, including bacteria, fungi, virus, or other microorganisms.
- sequences of nucleic acids belong to a virus, according to the Baltimore classification, Group I - double- stranded DNA viruses (ex. Adenovirus, herpes virus, Poxvirus), Group II - single-stranded DNA viruses (ex. Parvoviruses), Group III - double-stranded RNA viruses (Ex. Reovirus), Group IV - positive sense single-stranded RNA viruses (ex. Coronavirus, Picornavirus, Togavirus), Group V - negative or anti-sense single-stranded RNA viruses (ex.
- Group I - double- stranded DNA viruses ex. Adenovirus, herpes virus, Poxvirus
- Group II - single-stranded DNA viruses ex. Parvoviruses
- Group III - double-stranded RNA viruses Ex. Reovirus
- Group IV - positive sense single-stranded RNA viruses ex. Coronavirus, Picornavirus, Togavirus
- sequences of nucleic acids belong to a virus of the Coronaviridae family, and, particularly, to the severe acute respiratory syndrome coronavirus 2 (SARS- Cov-2).
- SARS- Cov-2 severe acute respiratory syndrome coronavirus 2
- the reverse transcription can be carried out using a polymerase DNA enzyme with reverse transcriptase activity, such as HIV-1, M-MLV, AMV, among others.
- a polymerase DNA enzyme with reverse transcriptase activity such as HIV-1, M-MLV, AMV, among others.
- the polymerase DNA enzyme with reverse transcriptase activity can, or not, be coupled reversibly to an aptamer, which inhibits its activity at temperatures below 40 °C.
- the isothermal amplification can be executed using an isothermal amplification method, such as: Loop-mediated isothermal amplification (LAMP), Helicase-Dependent Amplification (HDA), Rolling Circle Amplification (RCA), Strand Displacement Amplification (SDA), Multiple Displacement Amplification (MDA), Recombinase Polymerase Amplification (RPA), Transcription Mediated Amplification (TMA), Nucleic Acid Sequenced Based Amplification (NASBA), among others.
- LAMP Loop-mediated isothermal amplification
- HDA Helicase-Dependent Amplification
- RCA Rolling Circle Amplification
- SDA Strand Displacement Amplification
- MDA Multiple Displacement Amplification
- RPA Recombinase Polymerase Amplification
- TMA Transcription Mediated Amplification
- NASBA Nucleic Acid Sequenced Based Amplification
- thermostable polymerase DNA enzyme with strand displacement activity such as the Bst enzyme, among others.
- thermostable polymerase DNA enzyme with strand displacement activity can, or not, be reversibly coupled to an aptamer, which inhibits the activities thereof at temperatures lower than 40 °C.
- thermostable polymerase DNA enzyme with strand displacement activity can also have reverse transcriptase activity, allowing carrying out the reverse transcription and isothermal amplification with just one enzyme, such as the Bst enzyme, among others.
- the reaction mixture of the reverse transcription amplification and/or isothermal amplification can be comprised of a combination of oligonucleotide primers, dNTPs, thermostable polymerase DNA with strand displacement activity and/or polymerase DNA enzyme with reverse transcriptase activity, buffer optimised for the activity of the polymerase DNA enzymes, and reagent for discrimination in real time of the amplified fragments.
- the reverse transcription and/or isothermal amplification is carried out at a temperature from 37 °C to 70 °C, preferably at 65 °C, during an interval of more than 10 minutes, preferably between 30 to 60 minutes.
- the real-time discrimination of the amplified fragments can be made in an indirect or direct form using one or more reagents.
- the indirect real-time discrimination of the amplified fragments is made using a pH colourimetric indicator agent, such as phenol red, among others, or a DNA intercalating fluorescent reagent, such as SYBR green, among others.
- a pH colourimetric indicator agent such as phenol red, among others
- a DNA intercalating fluorescent reagent such as SYBR green
- the direct real-time discrimination of the amplified fragments is made using one or more oligonucleotide probes with complementary specific sequence to one or more region (s) of the relatively conserved amplified fragment(s).
- the oligonucleotide probes are conjugated with a fluorophore, such as, for example, FAM, HEX, ROX or Cy5, or similar, and/or a quencher, such as, for example, DABCYL, BHQ-1, BHQ-2, BHQ-3, or similar, or a combination of both.
- a fluorophore such as, for example, FAM, HEX, ROX or Cy5, or similar
- a quencher such as, for example, DABCYL, BHQ-1, BHQ-2, BHQ-3, or similar, or a combination of both.
- the oligonucleotide probes are RNA, DNA, LNA or PNA probes.
- the reverse transcription reaction and/or isothermal amplification results from the addition of a sample of extracted and purified RNA or DNA of samples presumably containing target nucleic acids, such as oral swabs, nasopharynx or nasal samples, blood, urine, saliva, sputum, faeces, environmental or food samples, or from surface contact, among others, or with the direct addition without extraction and purification of the RNA or DNA of these same samples to the reaction amplification mixture.
- target nucleic acids such as oral swabs, nasopharynx or nasal samples, blood, urine, saliva, sputum, faeces, environmental or food samples, or from surface contact, among others, or with the direct addition without extraction and purification of the RNA or DNA of these same samples to the reaction amplification mixture.
- the collection of samples to be analysed can be performed using a swab, syringe, collection tube or any other device designed for collection of samples.
- the method is characterised by the presence and consequent reverse transcription and/or isothermal amplification of a target sequence resulting in an alteration in colourimetric or fluorescence intensity, detected by the spectrophotometric sensor(s) (7) of the portable device (1).
- samples potentially containing viral particles of SARS-CoV-2 or the exposed viral RNA itself can be carried out in several manners, depending on the type of sample: a) Samples from the human or animal upper respiratory tract, including:
- swab Exudate from the nasopharynx, collected by swab and placed in tube containing up to 3mL of medium for transport of viruses, or saline solution, or another solution liable to lyse the viral particles and/or preserve the viral RNA intact.
- the swab must be inserted in one of the nostrils parallel to the palate until a slight resistance is felt. Leave the swab for a few seconds for absorption of the secretions. Gently remove with a rotating movement and repeat the collection in the other nostril.
- Oropharyngeal exudate collected by swab and placed in tube containing up to 3mL of medium for transport of viruses, or saline solution, or another solution liable to lyse the viral particles and/or preserve the viral RNA intact.
- the swab must be inserted in the oral cavity and rubbed against the pharyngeal wall and the oropharyngeal pillars.
- Broncho alveolar lavage collected by sterile container for liquid samples.
- a synthetic fibre swab with a plastic stick must be used, or any other that does not inhibit the reverse transcription reaction and/or isothermal amplification or which can potentially degrade the viral RNA sample.
- the samples can be used for extraction and purification of viral RNA, using traditional extraction and purification methods for nucleic acids or commercial kits for the purpose.
- a fraction of the sample can be placed in an aqueous solution containing a buffer and one or more RNases inhibitor(s), whereby the lysing of the viral particles for release of the viral RNA for subsequent analysis can occur by means of osmotic, mechanical and/or temperature lysis during the isothermal amplification process.
- the reverse transcription and amplification reactions of the cDNA resulting from the reverse transcription are carried out in just one step. Furthermore, the amplification is made in an isothermal manner to be compatible with the reverse transcription reaction. As such, different isothermal amplification techniques can be used:
- HDA Helicase-Dependent Amplification
- TMA Transcription Mediated Amplification
- NASBA Nucleic Acid Sequenced Based Amplification
- the discrimination of the real-time amplification can be carried out in two ways:
- the amplification is carried out in an unspecific manner, whether by monitoring a variable that is associated with the target template amplification (for example, variation of the pH of the reaction, turbidity, etc.), or by means of the colourimetric or intercalating fluorescent reagents to double-stranded DNA produced throughout the reaction (when in presence of a positive template).
- a variable that is associated with the target template amplification for example, variation of the pH of the reaction, turbidity, etc.
- this indirect way is not desirable since it may report false positive results, which can occur if there is non-specific amplification of the template or even of the oligonucleotide primer dimers.
- the amplification is carried out in a specific manner, using specific oligonucleotide probes which specifically hybridise in a region of the amplified zone, producing an alteration to the signal that is proportional to the amplified DNA.
- specific oligonucleotide probes which specifically hybridise in a region of the amplified zone, producing an alteration to the signal that is proportional to the amplified DNA.
- Specific conjugated oligonucleotide probes with self-quenched fluorophore Specific conjugated oligonucleotide probes with a fluorophore at one of the ends and a quencher at the opposite end, whether in hairpin or linear form (for the cases where the polymerase DNA has exonuclease activity); Combination of a specific conjugated oligonucleotide probe with a fluorophore and a specific conjugated nucleotide probe with a quencher, which sequences are contiguous to approximate the fluorophore to the quencher in case both hybridize specifically with the amplified DNA.
- the reverse transcription and/or isothermal amplification can be made with the intention of amplifying and detecting only one region or several simultaneously, using a multiplex approach to this end.
- one of the regions can serve as internal control of the sample, for example, by using as the target organism maintenance genes to be tested (ex. human, animal, bacterial, viral, among others), such as for example the actin gene, GAPDH or ubiquitin.
- the target organism maintenance genes to be tested ex. human, animal, bacterial, viral, among others
- the sample to be tested does not originate from an organism (such as for example, surface or environmental samples)
- a control target sequence such as, for example, actin genes, GAPDH or ubiquitin, or another synthetic target.
- the present invention refers to an integrated system for the detection and identification of specific sequences of nucleic acids in suspected coronavirus samples with the presence of a portable device (1) controlled by a mobile application (9) which records the data acquired by the portable device (1), analyses and stores it in a remote server in a cloud (10).
- the present invention further refers to a method for the detection and identification of the referred specific sequences of nucleic acids in samples that are suspected to contain coronavirus which cover the portable device (1), the mobile application (9) and the remote server in a cloud (10), which work together as a system.
- the present invention comprises a portable device (1) which is complementary to the method, the purpose of which is to control the test and record the data which allow an analysis for the determination of a last result to be established.
- the device (1) comprises one or more of the following components: a) A microcontroller (MCU) (5) with integrated Wi-Fi and/or Bluetooth, such as for example, an ESP32, the purpose of which is to control the different components and administrate all the information generated by some of the components which generate data that is useful to the test, namely, by the temperature sensor (6) and spectrophotometric sensor (s) (7), all managed by a firmware.
- MCU microcontroller
- ESP32 spectrophotometric sensor
- the firmware controls the different components of the device (1), particularly: it maintains an isothermal temperature during the course of the test; it controls the lighting sources and records the spectral variations during the course of the test; it communicates bi-directionally with the mobile application by means of Bluetooth or Wi-Fi, or with a remote server in a cloud by Wi-Fi.
- One or more spectrophotometric sensor(s) (7) which allow the emission of photons to be quantified differentially in different wavelengths of the UV, visible and/or infrared spectrum, preferably with a resolution less than or equal to 40nm.
- the detection is performed by subtraction of the photons, usually from white light, generated by the lighting system at 180° from the spectrophotometric sensor, and which are absorbed by the sample present in the reaction container.
- the detection is performed after excitation of the fluorophores using the lighting sources at 90° from the spectrophotometric sensor (7), and consequent detection by the spectrophotometric sensor (7) of the emission of photons generated by the excited fluorophore (s).
- These sensors (7) can be of the photovoltaic, photodiode, photoresistor, or phototransistor type, and may be coupled to light filters, for example a band-pass filter, to better define the spectral detection zone.
- All the photons detected by the spectrophotometric sensor (s) (7) are communicated to the MCU (5) by electronic means.
- One or more lighting sources (3) the purpose of which is to help the spectrophotometric sensor (s) (7) read the colourimetric or fluorescence changes, by means of the absorption of the light thereof emitted by the reagent (s) used in the real-time discrimination of the amplified fragments.
- These lighting sources (3) can be of the incandescent type, light-emitting diode (LED), laser (light amplification by stimulated emission of radiation) or any other source for emitting photons, and may be coupled to light filters, for example band-pass filter, to better define the spectral zone of the emission, emitting photons with a wavelength that is compatible with the selective excitation of the fluorophores of the probes, or in a broad visible spectrum.
- a heat source (8) the purpose of which is to heat the reaction container (2) to an optimum temperature for the DNA polymerase enzymes to work.
- This source (8) can be constituted by one or more resistor (s), Peltier module or any other heat source that is capable of reaching 100 °C and a minimum of 4 °C above room temperature.
- a temperature sensor (6) the purpose of which is to measure the temperature generated by the heat source (8) so that, with the help of the MCU (5), it is possible to "thermostatise” the heating of the reaction container (2) at the optimum temperature for the DNA polymerase enzymes to work, further guaranteeing that the inactivation temperature thereof is not reached inadvertently.
- the temperature sensor (6) is of the thermistor type (NTC or PTC), thermoresistance (RTD), thermocouple (ex.
- Battery (4) the purpose of which is to charge and operate the portable device (1) in an autonomous manner for a period of time, which allows for the execution of at least one test.
- the battery (4) is charged by DC charging, which can also charge the device (1) alternatively to the battery (4).
- the rechargeable battery (4) can be constituted by ion- aluminium, -lithium, -potassium or -magnesium, carbon, of flow (vanadium or zinc), lead-acid or polymer based, among others.
- the portable device (1) is controlled by a mobile application (9) connected to a remote server in a cloud (10) so that there is transmission of data and commands between the portable device (1), the mobile application (9) and the remote server in a cloud (10).
- the portable device (1) can also connect itself directly to the remote server in a cloud (10) for data transmission.
- the reaction mixture is incubated in the portable device (1) at a constant temperature between 37 °C and 70 °C for 30 minutes, and this time can be extended up to 90 minutes, or even 120 minutes, according to the isothermal amplification technique used.
- the monitoring of the amplification of the sample is carried out indirectly using fluorescent intercalating reagents (ex. SYBRTM green) and/or directly using the specific oligonucleotide probes marked with fluorophore (ex. FAM, HEX, ROX or Cy5, or similar), using the respective source of lighting (3) as excitation source of the fluorophore and its emission recorded by the spectrophotometric sensor (7) in different wavelengths of the visible/infrared UV spectrum (315 to 1400nm, in 40nm intervals at most).
- the same sensor (7) may also monitor alterations to the colour of the reaction mixture, as a form of determining indirectly whether amplification occurred or not.
- the entire process is started and controlled using a mobile application (9), which analyses the data of the spectrophotometric sensor (7) throughout the time to determine the final result.
- the present invention further comprises a mobile application (9) which connects with the portable device (1) by means of Bluetooth or, optionally by means of Wi-Fi.
- the mobile application (9) for control of the portable device (1) is compatible with Android or iOS, or any other operating system for a mobile device.
- the mobile application (9) carries out the processing of the data generated by the portable device (1) and communication of same to the remote server in a cloud (10).
- the application (9) allows for making the record of the test by using the camera of the mobile device to record the barcode associated to the reagent tube which contains the reaction mixture, to be able to record the reference of the test that it will process.
- the mobile application (9) communicates with the remote server in a cloud (10) in order to collect the parameters of the test (time, temperature, data to be analysed, cut-off for analysis, etc.) and transfers these parameters to the portable device (1) to be able to start the test.
- the mobile application (9) also allows for recording the user ID, the sample ID and to attribute a sole ID to the test (which is attributed by the remote server in a cloud (10)).
- the application (9) also records the location of the test to allow a geographic follow-up of epidemics/pandemics, while safeguarding the anonymity of the personal data of the user.
- the test transfers to the application (9) the data collected by the spectrophotometric sensor (7) during the course of the test.
- This data will be analysed by the mobile application (9), which will consider positive, a sample of which the variation in fluorescence intensity in the respective wavelengths of emission of the fluorophore used is higher than 10% of the initial signal of fluorescence, and when this occurs in a time less than 1600 seconds (this cut-off may vary between 700 and 3000, according to the test in question).
- the monitoring can also be made in multiplex, using more than one specific oligonucleotide probe marked with different fluorophores (ex. FAM, HEX, ROX or Cy5, or similar) which can be monitored in distinct wavelengths (ex. 520nm, 556nm, 602nm, 670nm, among others).
- the present invention further comprises a remote server in a cloud (10) which stores and processes the data from all the tests in a centralised manner as well as the parameters used (reaction time, reaction temperature, data to be recorded, intervals of data to be recorded, parameters for analysis of the results, among others) for each of the tests that can be carried out on the portable device (1).
- the server (10) further attributes, by means of the mobile application (9), one sole ID for each one of the tests, associating this ID with the results and other information (sample ID, location of test, user, among others).
- the server (10) can also include an artificial intelligence algorithm for a dynamic analysis of all the data united therein, as well as timely alerting the respective health entities. All the data in the server (10) is encrypted to safeguard the cyber-security of all the data stored and being transmitted between server and mobile application (9) and/or portable device (1).
- the sample to be analysed is usually collected with a swab and placed in a tube containing up to 3mL of medium for transport of viruses, or saline solution, or another solution capable of lysing the viral particles and/or preserving the viral DNA intact.
- a fraction between 1 and 40 microlitres of this aqueous medium is added to the reaction mixture previously prepared and provided to the final user.
- the collected samples can be processed for the extraction and purification of the viral RNA, using traditional extraction and purification methods for nucleic acids or commercial kits for this purpose, resuspending the purified nucleic acids in distilled water (Type-I) free of ribonucleases, being subsequently used a fraction for analysis (between 1 and 40 microlitres) of these purified resuspended nucleic acids.
- distilled water Type-I
- oligonucleotide primers for the reverse transcription and isothermal amplification by the LAMP method, from different genomic regions relatively preserved of SARS-CoV-2. Namely, for the region: Table 1. RNA templates relative to regions of the genome of the coronavirus severe acute respiratory syndrome 2 (SARS- CoV-2).
- a set of oligonucleotide probes conjugated internally with a fluorophore was defined, which is self-quenched in the isolated form thereof, and which sequences hybridize in specific preserved zones of different genomic regions of the SARS-CoV-2, located in the fragment amplified by LAMP, whereby they work by including as oligonucleotide primers of direct or reverse loop, according to region.
- the fluorophore ceases to self-quench, increasing the emission of fluorescence thereof. Namely, these are the probes for each region: Table 3. Probes for specific discrimination of the reverse transcription and/or isothermal amplification of regions of the genome of the coronavirus severe acute respiratory syndrome 2 (SARS-CoV-2).
- the mixture of the LAMP reaction was optimised for the method for detection and identification of SARS-Cov-2 by means of the present invention, containing: 1.6mM of each nucleotide primer FIP and BIP; 0.2mM of each nucleotide primer F3 and B3; 0.4mM of each nucleotide primer LF or LB and of each specific oligonucleotide probe LB or LF, according to the region to be analysed; 1.4mM of each dNTP; 320 U/ml Bst DNA Polymerase; 500 U/mL Reverse Transcriptase; 20 mM Tris-HCl pH 8.8 @25 °C; 8mM (NH 4 ) 2 S0 4 ; lOmM MgS0 4 ; 50 mM KC1; and 0.1% Tween® 20. Table 4. Combination of oligonucleotide primers for the reverse transcription and/or isothermal amplification of regions of the genome of the coronavirus severe
- the final volume of the reaction mixture used is of 20 m ⁇ , considering a sample volume of 8m]3. However, the final volume of the reaction mixture can be proportionally adjusted between 5 to 100m]0.
- 20m]3 of mineral oil or liquid wax are added.
- PCR tubes of 0.2mL are used as a reaction container, and tubes from 0.1 mL to 0.5mL may also be used.
- the reaction mixture was incubated in the portable device (1) at a constant temperature of 65 °C for 30 minutes. At the end of that time, the data from the spectrophotometric sensor (7) was sent to the mobile application (9) and analysed.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT11631720 | 2020-04-30 | ||
PCT/IB2021/053530 WO2021220192A2 (en) | 2020-04-30 | 2021-04-28 | Method and portable device for detection of nucleic sequences in suspected coronavirus samples |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4142945A2 true EP4142945A2 (en) | 2023-03-08 |
Family
ID=75787159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21723396.4A Withdrawn EP4142945A2 (en) | 2020-04-30 | 2021-04-28 | Method and portable device for detection of nucleic sequences in suspected coronavirus samples |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4142945A2 (en) |
JP (1) | JP2023524117A (en) |
CN (1) | CN115836133A (en) |
AU (1) | AU2021265579A1 (en) |
BR (1) | BR112022021086A2 (en) |
CA (1) | CA3175648A1 (en) |
IL (1) | IL297281A (en) |
WO (1) | WO2021220192A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES1298031Y (en) * | 2022-02-11 | 2023-06-02 | Consorcio De Aguas De Asturias | WASTEWATER OR ENVIRONMENTAL ANALYSIS SYSTEM FOR THE DETECTION OF VIRUSES, BACTERIA OR EUKARYOTIC MICROORGANISMS |
WO2024047567A1 (en) * | 2022-08-31 | 2024-03-07 | VD-ING d.o.o. | Method, device and system for detecting microbial or viral infection |
US20240120087A1 (en) * | 2022-10-07 | 2024-04-11 | 1Drop Inc. | Method and apparatus for efficiently transmitting nucleic acid amplification result data made by measuring instrument |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
ZA936016B (en) | 1992-08-24 | 1994-03-10 | Akzo Nv | Method for nucleic acid amplification |
DE69937223T3 (en) | 1998-11-09 | 2011-05-05 | Eiken Kagaku K.K. | PROCESS FOR SYNTHESIS OF NUCLEIC ACIDS |
US6221603B1 (en) | 2000-02-04 | 2001-04-24 | Molecular Dynamics, Inc. | Rolling circle amplification assay for nucleic acid analysis |
AU2003272438B2 (en) | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
AU2004203649B2 (en) | 2003-08-12 | 2006-01-12 | F. Hoffmann-La Roche Ag | Thermostable Taq polymerase fragment |
US9057097B2 (en) | 2009-06-05 | 2015-06-16 | Alere San Diego Inc. | Recombinase polymerase amplification reagents and kits |
US20110312851A1 (en) * | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Device for high density spotting of oligonucleotides |
WO2015031351A1 (en) * | 2013-08-26 | 2015-03-05 | Diagenetix, Inc. | Hardware and mobile software for operation of portable instruments for nucleic acid amplification |
ITUB20159332A1 (en) | 2015-12-22 | 2017-06-22 | Diasorin S P A | Fluorescence detection procedure of loop-mediated isothermal amplification (LAMP) of a target nucleic acid, related oligonucleotides and kits. |
US20170276599A1 (en) * | 2016-03-24 | 2017-09-28 | The Board Of Regents Of The University Of Texas System | Cost effective battery-powered spectrophotometric system |
-
2021
- 2021-04-28 JP JP2022566717A patent/JP2023524117A/en active Pending
- 2021-04-28 BR BR112022021086A patent/BR112022021086A2/en unknown
- 2021-04-28 CA CA3175648A patent/CA3175648A1/en active Pending
- 2021-04-28 WO PCT/IB2021/053530 patent/WO2021220192A2/en unknown
- 2021-04-28 EP EP21723396.4A patent/EP4142945A2/en not_active Withdrawn
- 2021-04-28 AU AU2021265579A patent/AU2021265579A1/en active Pending
- 2021-04-28 CN CN202180031710.9A patent/CN115836133A/en active Pending
-
2022
- 2022-10-12 IL IL297281A patent/IL297281A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023524117A (en) | 2023-06-08 |
CN115836133A (en) | 2023-03-21 |
BR112022021086A2 (en) | 2022-12-13 |
WO2021220192A3 (en) | 2021-12-09 |
IL297281A (en) | 2022-12-01 |
WO2021220192A2 (en) | 2021-11-04 |
WO2021220192A4 (en) | 2022-02-03 |
AU2021265579A1 (en) | 2022-11-10 |
CA3175648A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021265579A1 (en) | Method and portable device for detection of nucleic sequences in suspected coronavirus samples | |
JP2017200483A (en) | Method and composition for sequence-specific purification and multiplex analysis of nucleic acid | |
US11149320B1 (en) | Assays for the detection of SARS-CoV-2 | |
Islam et al. | Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses | |
US11118206B2 (en) | Multiple stage isothermal enzymatic amplification | |
Srividya et al. | Loop mediated isothermal amplification: a promising tool for screening genetic mutations | |
Kubota et al. | Non-instrumented nucleic acid amplification (NINA) for rapid detection of Ralstonia solanacearum race 3 biovar 2 | |
JP2023527145A (en) | CRISPR-based assays to detect pathogens in samples | |
Eboigbodin et al. | Rapid and sensitive real-time assay for the detection of respiratory syncytial virus using RT-SIBA® | |
CN114058679A (en) | CRISPR cascade nucleic acid detection system and detection method and application thereof | |
JP6727137B2 (en) | Method for detecting multiple nucleic acids in a sample | |
Jones et al. | Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs | |
JP2018500024A (en) | Compositions and methods for detection of drug-resistant Mycobacterium tuberculosis | |
WO2022159874A1 (en) | Compositions, kits and methods for detection of viral variant sequences | |
CN106471135B (en) | Molecular detection of enteroviruses and echoviruses | |
Bikos et al. | SLAMP: a rapid fluorometric RT-LAMP assay for sensitive and specific detection of SARS-CoV-2 from human saliva | |
Diego et al. | A Simple, Affordable, Rapid, Stabilized, Colorimetric, Versatile RT-LAMP assay to detect SARS-CoV-2 | |
US20220195541A1 (en) | Detecting a target nucleic acid in a biological sample | |
US20220259680A1 (en) | SARS CoV-2 INFECTIVITY DETERMINATION ASSAY | |
US20230250493A1 (en) | Kit and methods for characterizing a virus in a sample | |
RU2699180C1 (en) | Set of oligonucleotide primers and a fluorescent-labeled probe for identifying rnas of burkholderia mallei sap excretion and burkholderia pseudomallei melioidosis based on transcription amplification (nasba) in real time mode | |
Joshi et al. | Point-of-Care Diagnostics Using Molecular Approaches | |
Gupta et al. | Polymerase Spiral Reaction (PSR) for the Diagnosis of Porcine Viral Diseases | |
Bhat et al. | Real-Time Polymerase Chain Reaction | |
Wang et al. | SARS-CoV-2 detection with type IA CRISPR “FALCON” system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221026 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231101 |